BSF ENTERPRISE PLC

Regulatory Filings • Oct 9, 2023

National Storage Mechanism | Additional information

RNS Number : 4124P

BSF Enterprise PLC

09 October 2023

9 October 2023

BSF Enterprise PLC

("BSF" or the "Company")

Participation in The ThinkEquity Conference

BSF Enterprise PLC (LSE: BSFA) (OTCQB: BSFAF), a company focused on unlocking the next generation of biotechnological solutions using cell-based tissue engineering, will be participating in The ThinkEquity Conference, which will take place on October 19, 2023, at The Mandarin Oriental Hotel in New York.

Che Connon, CEO and Director will be presenting at 10:30 AM ET on October 19th. Interested parties can register to attend here. Members of the BSF Enterprise PLC management will also be holding one-on-one investor meetings throughout the day.

About BSF Enterprise PLC

BSF Enterprise PLC (BSF) is focused on unlocking the next generation of biotechnological solutions - using cell-based tissue engineering to help generate cultured meat, lab-grown leather, as well as human corneas, collagen growth and skin substitutes, as part of a radical transformation to deliver sustainable solutions across a variety of sectors. It owns 100% of 3D Bio-Tissues (3DBT), a tissue engineering with patent-protected IP that is already producing human corneas to help restore vision to millions of people and successfully produced the UK's first high-quality lab-grown meat from its laboratory in Newcastle in 2023. BSF aims to deliver growth to shareholders through the continued commercialisation of 3DBT's IP, which has multiple applications, as well as through M&A. It aims to acquire a suite of technologies that underpins the development of tissue templating for corneas, meat and leather, and license out the IP to manufacturers, wholesalers and distributors to help manufacture the products at scale.

About The ThinkEquity Conference

The ThinkEquity Conference will gather industry insiders, investors and leading executives from around the world on October 19th in New York. Attendees can expect a full day of company presentations, one-on-one investor meetings, networking and more.

Featured sectors include AI, Technology, Biotechnology, EV/EV Infrastructure, Metals and mining and Energy. To register to attend The ThinkEquity Conference, please follow this link.

For further enquiries, please visit www.bsfenterprise.com or contact:

BSF Enterprise PLC	Via SEC Newgate below
Geoff Baker - Executive Director Che Connon - CEO & Director
Shard Capital (Broker)
Damon Heath Isabella Pierre	0207 186 9000 0207 186 9927
SEC Newgate (Financial Communications)
Bob Huxford Elisabeth Cowell George Esmond	020 3757 6882 BSF@secnewgate.co.uk

ISIN of the Ordinary Shares is GB00BHNBDQ51

SEDOL Code is BHNBDQ5.

Notes to Editors

BSF Enterprise PLC (BSF) is focused on unlocking the next generation of biotechnological solutions - using cell-based tissue engineering to help generate cultured meat, lab-grown leather, as well as human corneas, collagen growth and skin substitutes, as part of a radical transformation to deliver sustainable solutions across a variety of sectors.

It owns 100% of 3D Bio-Tissues (3DBT), a tissue engineering with patent-protected IP that is already producing human corneas for testing to help restore vision to millions of people. Building on this success, it has produced the UK's first high quality lab-grown meat from its laboratory in Newcastle, transforming the meat-production industry towards an ethical and sustainable practice. 

BSF aims to deliver growth to shareholders through the continued commercialisation of 3DBT's IP, which has multiple applications, as well as through M&A. It aims to acquire a suite of technologies that underpins the development of tissue templating for corneas, meat and leather, and license out the IP to manufacturers, wholesalers and distributors to help manufacture the products at scale. 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NRAUKOWROUURRRA